Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Valencia – page 97

1 800 clinical trials in Valencia, Spain across 8 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Valencia at a glance
1 800
clinical trials
  • Research sites8
Type of trial
Recruitment status
Quick filters

1 800 trials in Valencia

Open in trial search

K-ras gene mutation+3

Not recruiting

Study of JDQ443, TNO155, and Tislelizumab for Patients with Advanced Solid Tumors with KRAS G12C Mutation

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Batoprotafib
  • Sponsor:Novartis Pharma AG

Anaemia+1

Not recruiting

Study on KER-050 and Ruxolitinib for Patients with Myelofibrosis and Anemia

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

Study of IMGN632, Venetoclax, and Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

Not recruiting
Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Colorectal cancer

Not recruiting

Comparing Pain Relief Methods in Colorectal Cancer Surgery: TAP Block vs. Port Site Infiltration with Levobupivacaine for Patients in ERAS Program

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Levobupivacaine
  • Sponsor:Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana

Neoplasm

Not recruiting

Study of EGL-001 for Adults with Advanced or Metastatic Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:EGL-001
  • Sponsor:Egle Therapeutics

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Ribociclib and Palbociclib for Patients with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Palbociclib
  • Sponsor:Solti Group

Post breast therapy pain syndrome

Not recruiting

Study on Botulinum Toxin Type A and Capsaicin for Treating Postmastectomy Pain in Women After Breast Cancer Surgery

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Capsaicin
  • Sponsor:Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana

Neoplasm

Not recruiting

Study of RLY-4008 for Patients with Cholangiocarcinoma and Other Advanced Solid Tumors

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:RLY-4008
  • Sponsor:Elevar Therapeutics Inc.

Study on the Safety of TAK-755, Rituximab, and Glucocorticoids for Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP)

Not recruiting
Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Apadamtase Alfa
  • Sponsor:Takeda Development Center Americas Inc.

Gastrointestinal stromal tumour

Not recruiting

Study Comparing Ripretinib and Sunitinib for Patients with Advanced Gastrointestinal Stromal Tumors Previously Treated with Imatinib

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ripretinib
  • Sponsor:Deciphera Pharmaceuticals Inc.

Plasma cell myeloma

Not recruiting

Study of Elranatamab for Patients with Multiple Myeloma Resistant to Proteasome Inhibitors, Immunomodulatory Drugs, and Anti-CD38 Antibodies

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Elranatamab
  • Sponsor:Pfizer Inc.

Fallopian tube cancer+2

Not recruiting

Study of Nemvaleukin Alfa and Pembrolizumab for Patients with Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Nemvaleukin Alfa
  • Sponsor:Mural Oncology Inc.

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Valencia

What the registry says about research in the country

01 Oncology & Hematology

Innovative research focused on Mantle Cell Lymphoma treatments and Immune Thrombocytopenia, evaluating novel therapeutic combinations and investigating new treatment approaches.

  • Lymphoma therapies
  • Blood disorders
  • Immunotherapy combinations

Studies aim to improve treatment outcomes and provide alternative therapeutic options for patients.

02 Respiratory Medicine

Comprehensive studies addressing Respiratory Syncytial Virus, ARDS, and COPD, with focus on innovative treatments and preventive measures.

  • Viral respiratory infections
  • Acute respiratory conditions
  • Vaccine development

Research emphasizes both therapeutic interventions and preventive strategies for respiratory diseases.

03 Neurology & Stroke

Advanced research into acute ischemic stroke treatments and outcomes, investigating novel therapeutic approaches for better patient recovery.

  • Stroke treatment
  • Neurological recovery
  • Reperfusion therapies

Focus on improving functional outcomes and reducing complications in stroke patients.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.